Clinical Trials in North Carolina

Showing 13401-13420 of 20,428 trials

A Study of Ixekizumab in Participants With Plaque Psoriasis

NCT02993471

This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam) that are metabolized by cytochrome P450. Each participant will complete two study periods. Participants will take the mixture of commonly used drugs (plus vitamin K) by mouth on 3 occasions (prior to treatment with ixekizumab and after 1 and 12 weeks of treatment with ixekizumab). The study will last about 17 weeks, including follow-up. Screening must be completed prior to study start.

Psoriasis

Eli Lilly and Company28 participantsStarted Dec 2016

Anaheim, California, United States • DeLand, Florida, United States • High Point, North Carolina, United States

UNKNOWN46 miles

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

NCT01372787

This clinical trial studies the quality of life and care needs of patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or peritoneal cancer. Studying quality of life in patients with cancer may help determine the effects of gynecologic cancer and may help improve the quality of life for future cancer survivors.

AnxietyFatigueNausea and Vomiting+20 more

Gynecologic Oncology Group103 participantsStarted Apr 2011

Aurora, Colorado, United States • Hartford, Connecticut, United States • Hartford, Connecticut, United States +141 more locations

A Study of Ixekizumab in Participants With Plaque Psoriasis

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Find Trials by Condition in North Carolina

Driveline Silicone Skin Interface Registry

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Blood and Plasma Collection For Use in Future Clinical Trials

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Validation of Non-Invasive Intracranial Pressure (ICP) Monitoring Device

Dating Matters: Strategies to Promote Healthy Teen Relationships

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Hemophilia B Gene Therapy With AAV8 Vector

Inflammation and the Host Response to Injury (Trauma)

Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE)

Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis